{"id":"NCT00467519","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age","officialTitle":"Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine as Fifth Dose Booster in Children 4 to 6 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2009-11","completion":"2009-12","firstPosted":"2007-04-30","resultsPosted":"2010-12-03","lastUpdate":"2014-02-07"},"enrollment":1045,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Tetanus","Diphtheria","Pertussis"],"interventions":[{"type":"BIOLOGICAL","name":"Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)","otherNames":["Adacel"]},{"type":"BIOLOGICAL","name":"DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)","otherNames":["DAPTACEL in the US","TRIPACEL in Canada"]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"}],"summary":"Currently, there is no 5-component acellular pertussis vaccine licensed for the 5th dose in US children aged 4 to 6 years.This study is aimed at providing evidence of sero-protection, booster response and safety of this formulation as a 5th dose.\n\nPrimary Objective:\n\n\\- To compare the immune responses of Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) Vaccine to Diphtheria, tetanus and acellular pertussis (DTaP) vaccine (all antigens) when each is administered as a 5th dose and given concurrently, to children aged 4 to 6 years.\n\nSecondary/Observational Objectives:\n\n* To compare the immune responses for pertussis antigens of Tdap Vaccine to DTaP vaccine (for pertussis antigens) when each is administered as a 5th dose and given concurrently, to children aged 4 to 6 years.\n* To present the long-term immunogenicity at 1-, 3-, and 5-years post-vaccination after each long-term follow-up.\n* To describe the safety profile following vaccine administration.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Seroprotection at Baseline and 30 Days Post-vaccination for Diphtheria and Tetanus at â‰¥ 0.1 IU/mL Level","timeFrame":"Pre-dose and 30 days post-vaccination","effectByArm":[{"arm":"Tdap Vaccine Group","deltaMin":65,"sd":null},{"arm":"DTaP Vaccine Group","deltaMin":69,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":43,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":531},"commonTop":["Increased left limb circumference","Solicited Injection Site Pain","Increased right limb circumference","Myalgia","Injection site Erythema"]}}